Keytruda Biosimilar Sponsors Await Merck’s Subcutaneous Data

Potential For 2024 Launch Would Protect 2028 Intravenous LOE

 
• By Dean Rudge
  
Subcutaneous injection
Keytruda SC has the potential for major conversion • Source: Shutterstock

More from Biosimilars

More from Products